Comparison of the prognostic value of different inflammation-based scores in patients with hepatocellular carcinoma after Lenvatinib therapy

Figure 1 Kaplan-Meier curves of the overall survival of hepatocellular carcinoma patients after Lenvatinib therapy. A: C-reactive protein; B: C-reactive protein-to-albumin ratio; C: Lymphocyte-to-C-reactive protein ratio; D: Lymphocyte-to-monocyte ratio; E: Neutrophil-to-lymphocyte ratio; F: Platelet-to-lymphocyte ratio; G: Prognostic nutritional index; H: Systemic immune-inflammation index. CRP: C-reactive protein; PLR: Platelet-to-lymphocyte ratio; NLR: Neutrophil-to-lymphocyte ratio; LCR: Lymphocyte-to-C-reactive protein ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune-inflammation index; CAR: C-reactive protein-to-albumin ratio; PNI: Prognostic nutritional index.

Figure 2 Nomogram and calibration curves for predicting 1- and 2-year overall survival in hepatocellular carcinoma patients treated with Lenvatinib. A: Nomogram for predicting the probability of 1- and 2-year overall survival (OS) in hepatocellular carcinoma patients after Lenvatinib therapy; B: Calibration curve for predicting patient OS at 1 year; C: Calibration curve for predicting patient OS at 2 years. OS: Overall survival; PNI: Prognostic nutritional index.

Figure 3 Time-dependent area under the curve analyses by receiver operating characteristic curves and plots to validate prognostic accuracy of the nomogram and inflammation-based scores in hepatocellular carcinoma patients treated with Lenvatinib. A: The area under the curve (AUC) values for time-dependent receiver operating characteristic curves verified the prognostic accuracy of the nomogram; B: Time-dependent AUC plot of survival predicted by the inflammation-based scores and the nomogram. AUC: Area under the curve.